HLB Group Strengthens Expertise with Division-Wide Chief Responsibility System

HLB Group is strengthening its professional management system by consecutively appointing chief officers for major divisions. This is a measure to enhance cooperation and work efficiency among affiliates through integrated operations by the top executives in each field.

HLB Group recently announced on the 2nd that it has appointed President Kim Jong-won as Chief People Officer (CPO) and President Hwang Jae-i as Chief Marketing Officer (CMO) during its recent group executive personnel reshuffle. Following the earlier appointments this year of President Han Yong-hae as Chief Technology Officer (CTO) for group bio technology and President Choi Soo-hwan as Chief Strategy Officer (CSO) for bio strategy, the group is establishing a professional responsibility management system for its C-level executives.

HLB Group is developing various new drug substances such as synthetic new drugs, cell therapies, and cancer vaccines through multiple affiliates. Based on the leadership of the top executives in each division, the group plans to strengthen bio technology development and activate personnel exchange and cooperation. With the anticancer drug Rivoceranib entering the New Drug Application (NDA) stage for first-line treatment of liver cancer, the group is also moving forward with establishing integrated global sales and marketing strategies.

CPO Kim Jong-won graduated from Yonsei University with a degree in economics and earned a master's degree in labor relations and a doctorate in economics. He has worked at Shinhan Bank, SoftBank Finance, and Merrill Lynch Securities, served as CEO of ACA Investment, and later joined HLB Group, where he served as CEO of HLB Power and HLB Global.

CMO Hwang Jae-i studied at Northwestern University in the United States and earned a bachelor's degree in marketing and a master's degree in advertising marketing from the University of Illinois at Urbana-Champaign. He was responsible for overseas marketing of the diabetes treatment Avandia at the American pharmaceutical company GlaxoSmithKline (GSK). Domestically, he served as head of international business at Dong-A Pharmaceutical, head of global business at JW Holdings, and head of international business at Youngjin Pharmaceutical. He joined HLB Group in March last year.

In addition to group personnel changes, President Baek Yoon-gi was appointed as Chief Operating Officer (COO) of HLB. Former Vice President Kim Kwang-jae was newly appointed as CEO of HLB Global, and Vice President Lee Dong-joo was appointed as Chief Financial Officer (CFO) of HLB Global. HLB Innovation, which recently changed its name after acquisition, newly recruited Lee Byung-geol, CEO of Verismo Asia, as Vice President and Head of Bio Strategy.

An HLB Group official stated, "While strengthening the authority and responsibility of the top executives in each division, we are introducing an overall responsibility system to increase synergy through organic cooperation among affiliates. We will focus on performance creation through flexible and efficient decision-making."

This content was produced with the assistance of AI translation services.